Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47
Pharmacology, Toxicology and Pharmaceutical Science
1
7%
Nursing and Health Professions
1
7%
Unknown
13
87%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 117. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2025.
All research outputs
#451,428
of 34,306,620 outputs
Outputs from RMD Open
#28
of 1,610 outputs
Outputs of similar age
#5,583
of 349,236 outputs
Outputs of similar age from RMD Open
#1
of 44 outputs
Altmetric has tracked 34,306,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,610 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,236 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.
